





RESEARCH  
ARTICLE

-  Cuneyd Yavas<sup>1</sup>  
 Nezh Hekim<sup>1</sup>  
 Lutfiye Karcioğlu Batur<sup>1</sup>  
 Recep Eroz<sup>2</sup>  
 Ahmet Ozaydin<sup>3</sup>

<sup>1</sup> Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul, Türkiye

<sup>2</sup> Department of Medical Genetics, Medical Faculty, Aksaray University, Aksaray, Türkiye

<sup>3</sup> Department of Medical Genetics, Cerrahpaşa Faculty of Medicine, Istanbul University, Istanbul, Türkiye

**Corresponding Author:**  
Lutfiye Karcioğlu Batur  
mail: lbatur@biruni.edu.tr

Received: 03.10.2024  
Acceptance: 23.03.2025  
DOI:10.18521/ktd.1560608

**Konuralp Medical Journal**  
e-ISSN1309-3878  
konuralptipdergi@duzce.edu.tr  
konuralptipdergisi@gmail.com  
www.konuralptipdergi.duzce.edu.tr



## Biomarkers of Vitamin D Sufficiency: Vitamin D Metabolite Levels do not depend on 25-Hydroxyvitamin D<sub>2</sub> levels in Healthy Turkish Individuals

### ABSTRACT

**Objective:** Patient-specific factors may influence the adequate supplemental vitamin D dose. In this study, we evaluated the relationship between 25(OH)D<sub>2</sub> and free vitamin D levels and vitamin D deficiency in a healthy Turkish population.

**Method:** Blood samples were obtained from 92 healthy adults aged ≥18 years. Total 25(OH)D was determined by CMIA. Serum 25(OH)D<sub>3</sub> and D<sub>2</sub> levels were measured by LC-MS. Free 25(OH)D was calculated according to the Bikle method.

**Results:** In 54% of the participants, 25(OH)D<sub>3</sub> levels were below 20 ng/mL. Those with 20 ng/mL or higher had higher mean serum 25(OH)D<sub>3</sub> and free vitamin D levels (P<0.001). Mean 25(OH)D<sub>2</sub> concentration did not differ according to deficiency criteria. Serum 25(OH)D<sub>2</sub> levels were consistent regardless of free vitamin D concentrations.

**Conclusions:** Serum 25(OH)D<sub>3</sub> and free vitamin D concentrations measured by LC-MS indicate deficiency by influencing the total 25(OH)D<sub>3</sub> concentration. However, serum 25(OH)D<sub>2</sub> concentration did not differ between individuals and does not directly indicate deficiency.

**Keywords:** Vitamin D, 25-Hydroxyvitamin D<sub>2</sub>, 25-Hydroxyvitamin D<sub>3</sub>, free vitamin D.

## D Vitamini Yetersizliğinin Biyobelirteçleri: Sağlıklı Türk bireylerde D Vitamini Metabolit Düzeyleri 25-Hidroksivitamin D<sub>2</sub> Düzeylerine Bağlı Değildir

### ÖZET

**Amaç:** Hastaya özgü faktörler yeterli ek D vitamini dozunu etkileyebilir. Bu çalışmada, sağlıklı bir Türk popülasyonunda 25(OH)D<sub>2</sub> ve serbest D vitamini düzeyleri ile D vitamini eksikliği arasındaki ilişki değerlendirilmiştir.

**Yöntem:** 18 yaş üstü 92 sağlıklı yetişkinden kan örnekleri alınmıştır. Toplam 25(OH)D CMIA ile belirlenmiştir. Serum 25(OH)D<sub>3</sub> ve D<sub>2</sub> seviyeleri LC-MS ile ölçülmüştür. Serbest 25(OH)D hesaplaması Bikle yöntemine göre yapılmıştır.

**Bulgular:** Katılımcıların %54'ünde 25(OH)D<sub>3</sub> seviyesi 20 ng/mL'nin altındaydı. 20 ng/mL veya daha yüksek olanlarda, ortalama serum 25(OH)D<sub>3</sub> ve serbest D vitamini seviyeleri daha yüksekti (P<0.001). Ortalama 25(OH)D<sub>2</sub> konsantrasyonu eksiklik kriterlerine göre fark göstermemiştir. Serum 25(OH)D<sub>2</sub> seviyeleri, serbest D vitamini konsantrasyonlarından bağımsız olarak tutarlıydı.

**Sonuç:** LC-MS ile ölçülen serum 25(OH)D<sub>3</sub> ve serbest D vitamini konsantrasyonları, toplam 25(OH)D<sub>3</sub> konsantrasyonunu etkileyerek eksikliği göstermektedir. Ancak, serum 25(OH)D<sub>2</sub> konsantrasyonu bireyler arasında fark göstermemiştir ve eksikliği doğrudan göstermez.

**Anahtar Kelimeler:** D vitamini, 25-Hidroksivitamin D<sub>2</sub>, 25-Hidroksivitamin D<sub>3</sub>, serbest D vitamini

## INTRODUCTION

Vitamin D occurs predominantly in two forms: ergocalciferol ( $D_2$ ) and cholecalciferol ( $D_3$ ). Most vertebrates' skin produces around 80% of their  $D_3$  by UVB irradiation of 7-dehydrocholesterol. In contrast, UVB radiation produces vitamin  $D_2$  in plants and fungus (1). Vitamin D is essential for bone metabolism, among other metabolic and catabolic pathways, and functions in the congenital and adaptive immune systems that influence the cure, severity and mortality of various acute and chronic diseases and bacterial and viral illnesses (2-4). Multiple forms of vitamin D can play a key role in modulating immunity, including ergocalciferol ( $D_2$ ), cholecalciferol ( $D_3$ ), 25-hydroxyvitamin  $D_2$  ( $25(OH)D_2$ ), 25-hydroxyvitamin  $D_3$  ( $25(OH)D_3$ ), and 1,25-dihydroxyvitamin  $D_3$  ( $1,25-(OH)2D_3$ ) (5). The primary metabolic pathway for vitamin D physiology involves the formation of  $25(OH)D_2$  and  $25(OH)D_3$  from  $25(OH)D$  (6). Through the bloodstream, vitamin D and its metabolites are transported predominantly attached to vitamin D binding protein (VDBP) (about 85%) and albumin (about 15%) (7). Upon reaching target cells, the vitamin D complex dissociates from either VDBP or albumin, allowing vitamin D to enter the cells and engage with nuclear vitamin D receptors (VDRn), which are present in various tissues and act as transcriptional factors (8).

Vitamin D insufficiency is commonly defined as serum  $25(OH)D_3$  concentrations less than 20 nmol/L, while other recommendations and published research have varying cut-off values (9). It is often necessary to augment low serum  $25(OH)D_3$  levels with ergocalciferol ( $D_2$ ) or cholecalciferol ( $D_3$ ), although their therapeutic equivalency is debatable (10-12). Research indicates that taking  $D_3$  orally increases levels of both free and total  $25(OH)D$  more than using  $D_2$  supplements (10, 13, 14). Factors unique to each patient may also influence how much extra vitamin D is needed (15) and for this reason, it's critical to validate vitamin D metabolite thresholds as well as which metabolite is clinically meaningful in order to recommend vitamin D supplementation. This study provides a comprehensive analysis by including both  $25(OH)D_3$  and  $25(OH)D_2$  levels in a larger cohort, allowing for a more detailed evaluation of vitamin  $D_2$  status in healthy individuals. We present new findings on the potential role of  $25(OH)D_2$  in vitamin D metabolism, which has been largely overlooked in previous studies. Owing to variations in patient reactions to vitamin D therapy and demographic variables, our goal was to look at the relationship between  $25(OH)D_2$  and free vitamin D levels as well as vitamin D insufficiency in a cohort of Turkish adults who were otherwise in good health.

## MATERIAL AND METHODS

**Study Design:** Ninety-two healthy adults, aged 18 or older, of both sexes (38 men and 54 women), who applied for a normal yearly check-up at the Biruni University Hospital's Check-up Unit, satisfied the research's requirements, and consented to take part in the investigation were included in the study. The following three requirements were met in order to be eligible for this prospective study: 1) no health condition, such as obesity, that might influence vitamin D concentrations; 2) no vitamin D supplementation during the previous two years; and 3) at least two generations of Turkish ancestry. The exclusion criteria included the following: 1) refusing to participate in the study; 2) not being of Turkish ethnic descent; 3) taking any kind of vitamin D supplement in the previous two years; 4) having a diagnosis of an infectious disease that is actively active (such as acute hepatitis, AIDS, or tuberculosis); 5) using steroids or their derivatives in the previous two years; 7) being under the age of eighteen, pregnant, or nursing.

Ethics committee permission for the study was obtained from Biruni University Ethics Committee (Ethical approval number: 2020/43-20). This study was conducted in full compliance with the Helsinki Declaration. After notifying all subjects about the study, formal permission forms were obtained from each.

In our previous study, we genotyped vitamin D binding protein in 51 patients (16). In this study, we added 41 more patients to the patients and performed a different statistical study and biochemical analysis of vitamin  $D_2$  from a different perspective. In addition, the measurement differences between vitamin  $D_2$  and  $D_3$  levels were also revealed.

**Collection of Blood Samples:** Venous blood samples were taken and divided into two tubes: one for serum with a gel and the other for EDTA (Nest- UK). Blood samples collected in serum tubes at 4100 rpm and centrifuged (NF 800, Nuve, Turkey), the blood was split into two aliquots and stored at  $-80^{\circ}C$ .

**Metabolic Measurements of Vitamin D:**  $25(OH)D$  concentrations were evaluated using chemiluminescence microparticle immunoassay (CMIA). The Architect 25-OH Vitamin D kit (5P02, Abbott Diagnosis, USA) and i1000SR analyzer (Abbott Laboratories, USA) were used in the study. The 2011 IOM report on dietary reference intakes of 20 ng/ml was taken as the cut-off for vitamin D deficiency (17). To measure the albumin concentration of the samples, a Roche/Hitachi cobas C instrument was used in accordance with the manufacturer's instructions, which uses a colorimetric assay technique. Serum VDBP concentration was determined in accordance with the literature (18) and Quantikine kit for

monoclonal immunoassay measurement of human vitamin VDBP was performed using the manufacturer's instructions (R&D Systems, Cat No: DVDBP0, USA).

The analysis of 25(OH) D<sub>3</sub> and vitamin D<sub>2</sub> was conducted using liquid chromatography–mass spectrometry (LC-MS), employing an Agilent Infinity 1290 HPLC system (Agilent Technologies, Santa Clara, CA, USA). This system featured a binary pump (G4220A), column compartment (G1316C), and autosampler (G7167B), which were coupled to a 6470 triple quadrupole mass spectrometer (6470A, Agilent Technologies, Santa Clara, CA, USA). The process utilized a CE-in vitro diagnostic certified Jasem vitamin D LC-MS/MS analysis kit (Sem Laboratuvar Cihazlari Pazarlama Inc., Turkey).

For sample preparation, patient samples and serum-based calibrants/quality control materials were handled according to the kit's protocol. This procedure included a protein precipitation phase before injection into the system. The HPLC system was operated using the chromatographic parameters specified in the kit, and detection was performed with MS/MS using positive electronic spray ionization in multiple-reaction monitoring mode. For accurate measurement of analyte concentrations, the ratio of the peak area of vitamin D<sub>2</sub> (25(OH) D<sub>3</sub>) to the internal standard (labeled stable isotope-d6 25(OH) D<sub>3</sub>) was calculated. The Bikle Method, generally known as the following equation, was utilized to determine free 25(OH)D (19):

$$\text{Free 25(OH)D} = \frac{\text{Total 25(OH)D}}{(1 + (\text{KALB} \times [\text{ALB}]) + (\text{KDBP} \times [\text{VDBP}]))}$$

Where [VDBP] is the concentration of vitamin D binding protein, [KALB] is the affinity constant for 25(OH)D with albumin, and [ALB] is the albumin concentration. Similarly, KDBP is the affinity constant for 25(OH)D<sub>3</sub> with vitamin D binding protein.

The authors' previously published work (16) examined VDBP gene polymorphisms using data on blood 25(OH) D<sub>3</sub>, albumin, and VDBP concentrations of 51 people.

**Table 1.** Vitamin D metabolite levels of healthy individuals according to the gender

	Total (n = 92)	Male (n = 38)	Female (54)	P value
Total 25(OH)D <sub>3</sub> (ng/ml)	19.45 ± 13.08	16.78 ± 8.19	21.02 ± 15.83	0.413
25(OH)D <sub>2</sub> (ng/ml)	2.95 ± 0.46	3.00 ± 0.50	2.90 ± 0.42	0.375
25(OH)D <sub>3</sub> (ng/ml)*	18.74 ± 11.85	15.98 ± 8.77	20.85 ± 13.54	0.054
Free vitamin D (pg/ml)	3.89 ± 2.45	3.24 ± 1.83	4.17 ± 2.56	0.130

\*measured by LC-MS/MS

**Comparison of Vitamin D Metabolites:** Among the total participants, 54% had blood levels of total 25(OH) D<sub>3</sub> below 20 ng/mL, which led to a diagnosis of vitamin D insufficiency. Subjects with

**Statistical Analysis:** A priori power analysis was conducted using G\*Power 3.1.9.7 to determine the appropriate sample size for this study. The analysis was based on an expected effect size of 0.5, an alpha level of 0.05, and a statistical power of 95%. The results indicated that a minimum of 34 participants was required to achieve sufficient power. Since our study included 92 participants, we ensured adequate statistical power to detect significant effects.

The presentation of all the data was as mean ± standard deviation. Kolmogorov-Smirnov distance test was used to test the normality of all in-group variables. The numerical variables were compared to a normal distribution using an unpaired t-test with Welch correction. The correlation between 25-OH-Vit D<sub>2</sub> and 25-OH-Vit D<sub>3</sub> levels was assessed using Spearman's rank correlation coefficient due to the non-parametric nature of the data distribution. Statistical significance was defined as P<0.05. For all statistical analyses, GraphPad InStat ver. 3.06 (USA) was used.

**RESULTS**

**Patient Characteristics:** Ninety-two people had a mean age of 37.28 ± 15.23. Among the patients, 58.7% were female and 41.3% were male. Although there was a substantially greater 25(OH) D<sub>3</sub> in females compared to men, the mean concentration of total 25(OH) D<sub>3</sub>, 25(OH)D<sub>2</sub>, and 25(OH) D<sub>3</sub> as determined by LC-MS and free vitamin D did not differ significantly across genders (Table 1). Compared to males (17 ng/mL), women had mean 25(OH) D<sub>3</sub> concentrations of 22 ng/mL, which suggests that women had greater amounts of vitamin D<sub>3</sub>. Men and women have similar free vitamin D levels (pg/mL), indicating that while women have greater total 25(OH) D<sub>3</sub>, there is no discernible difference in free vitamin D levels between the sexes. Females show significantly higher levels of both 25(OH) D<sub>3</sub> and free vitamin D compared to males. This suggests that women in the sample have greater amounts of bioavailable (free) vitamin D in addition to having higher total vitamin D<sub>3</sub> levels.

total 25(OH) D<sub>3</sub> levels equal to or greater than 20 ng/mL had significantly higher mean concentrations of 25(OH) D<sub>3</sub> (measured by LC-MS) and free vitamin D compared to those with levels

below 20 ng/mL ( $P < 0.001$ ). However, there was no significant difference in the mean serum concentration of 25(OH) D<sub>2</sub> between the two

groups, based on the criteria for vitamin D deficiency (Table 2).

**Table 2.** Vitamin D metabolite levels of healthy individuals compared with the total 25- Hydroxyvitamin D<sub>3</sub> levels

	Total 25(OH)D <sub>3</sub> <20ng/ml (n = 50)	Total 25(OH)D <sub>3</sub> ≥ 20ng/ml (n = 42)	P value
25(OH)D <sub>2</sub> (ng/ml)	2.91 ± 0.48	2.99 ± 0.44	0.266
25(OH)D <sub>3</sub> (ng/ml)*	10.63 ± 5.36	28.40 ± 10.07	<0.001
Free vitamin D (pg/ml)	2.29 ± 1.31	5.82 ± 2.08	<0.001

\*measured by LC-MS/MS

Additionally, 30.4% of all participants had free vitamin D levels under 2 pg/mL. Individuals with serum free vitamin D levels of 2 pg/mL or higher showed significantly higher mean concentrations of both total 25(OH) D<sub>3</sub> and 25(OH) D<sub>3</sub>, compared to those with free vitamin D levels


below 2 pg/mL ( $P < 0.001$ ), as determined by LC-MS. Nevertheless, no significant differences were observed in the mean serum 25(OH)D<sub>2</sub> levels across subjects when categorized by free vitamin D levels (Table 3).

**Table 3.** Vitamin D metabolite levels of healthy individuals compared with the free vitamin D levels

	Free vitamin D < 2 pg/ml (n = 28)	Free vitamin D ≥ 2 pg/ml (n = 64)	P value
Total 25(OH)D <sub>3</sub> (ng/ml)	7.50 ± 2.59	23.75 ± 13.0	<0.001
25(OH)D <sub>2</sub> (ng/ml)	2.93 ± 0.41	2.94 ± 0.40	0.902
25(OH)D <sub>3</sub> (ng/ml)*	6.18 ± 2.88	23.41 ± 10.80	<0.001

\*measured by LC-MS/MS

The scatter plot analysis demonstrates the relationship between serum 25-OH-Vit D<sub>2</sub> and 25-OH-Vit D<sub>3</sub> levels. The Spearman correlation coefficient ( $r = 0,03062$ ) was calculated as ( $p = 0,7695$ ), indicating a weak correlation between the two variables (Figure 1). The trendline with confidence intervals suggests that higher levels of 25-OH-Vit D<sub>3</sub> are not strongly associated with variations in 25-OH-Vit D<sub>2</sub> levels.



**Figure 1.** Scatter plot showing the correlation between serum 25-hydroxyvitamin D<sub>2</sub> (25-OH-Vit

D<sub>2</sub>) and 25-hydroxyvitamin D<sub>3</sub> (25-OH-Vit D<sub>3</sub>) levels. Each dot represents an individual patient sample. The correlation was assessed using Spearman’s rank correlation coefficient ( $r = 0,03062$ ,  $p = 0,7695$ ). The dotted lines indicate the confidence interval of the regression trendline.

**DISCUSSION**

Serum total 25(OH)D is a widely used biomarker to assess vitamin D reserves and estimate human vitamin D status as it detects both forms of 25(OH)D<sub>2</sub> and 25(OH) D<sub>3</sub> (16). We looked into the relationship between the levels of 25(OH)D<sub>2</sub> and of free vitamin D and vitamin D insufficiency in a healthy Turkish population since the type of vitamin D (D<sub>2</sub> or D<sub>3</sub>) might impact the dosage response of 25(OH) D<sub>3</sub> to vitamin D<sub>3</sub>. The mean concentration of 25(OH) D<sub>2</sub> in serum did not differ among individuals according to Vitamin D deficiency criteria and to concentration of free vitamin D, and therefore does not directly indicate vitamin D deficiency. However, the mean concentration of 25(OH) D<sub>3</sub> measured by LC-MS and free vitamin D affects the total 25(OH) D<sub>3</sub> concentration measured by automated systems and may indicate vitamin D deficiency. These findings may point to gender-specific variations in vitamin

D exposure or metabolism, such as variations in vitamin D binding proteins or increased sun exposure (Table 1).

Over the previous 20 years, a number of sensitive and focused commercial tests have been created (16). The variations in the cross-reactivity of antibodies with epimers and/or metabolites, as well as the processes of vitamin D extraction, deproteinization, and purification, account for the variations among these tests. Even with these technological advancements, measuring 25(OH) D<sub>3</sub> concentration precisely and accurately remains difficult due to the presence of various hydrophobic vitamin D metabolites and fluctuating ratios of 25(OH) D<sub>2</sub> to 25(OH) D<sub>3</sub> in the bloodstream. These metabolites also have low free quantities in serum due to their ability to bind to lipids, albumins, and vitamin D binding protein (VDBP). Therefore, the challenges are attributable to the accuracy and sensitivity of assays which might result in discrepancies across different testing methodologies. Of these methods, automated immunoassays account for 90% of routine 25(OH)D testing because of their low manual labor requirements, high throughput, and automated sample handling (20). All immunoassays should assess D<sub>2</sub> and D<sub>3</sub> metabolites similarly (with equimolar reactivity), although detection of 25(OH) D<sub>2</sub> and 25(OH) D<sub>3</sub> largely depends on the antibody specificity. Immunoassays that are capable of detecting 25(OH) D<sub>2</sub> are unable to distinguish it from 25(OH) D<sub>3</sub> (21). Because it is significantly more sensitive than automated methods but also more costly, isotope-dilution LC-MS/MS is now the gold standard for 25(OH) D<sub>3</sub> testing (22). In the current investigation, we additionally assessed 25(OH) D<sub>3</sub> using LC-MS/MS and compared the results with the overall levels of 25(OH) D<sub>3</sub> determined by automated CMIA. The results demonstrate that there was consistency in the 25(OH) D<sub>3</sub> levels across the two techniques of assessment.

Several studies have demonstrated that vitamin D<sub>2</sub> in equimolar doses is less effective at increasing blood 25(OH) D<sub>3</sub> levels compared to vitamin D<sub>3</sub> (23-25). Additionally, research suggests that vitamin D<sub>3</sub> metabolites exhibit a stronger affinity for VDBP and interact differently with the vitamin D receptor compared to vitamin D<sub>2</sub> metabolites. Furthermore, the 25-hydroxylation rate of vitamin D<sub>3</sub> is higher than that of vitamin D<sub>2</sub> (26). Although the majority of commercially available vitamin D supplements are in the D<sub>3</sub> form, vitamin D<sub>2</sub> is still present in certain dietary sources and fortified foods. As a result, individuals may have varying contributions of 25(OH)D<sub>2</sub> to their total vitamin D levels, depending on their dietary intake and metabolism. Furthermore, evaluating both 25(OH)D<sub>3</sub> and 25(OH)D<sub>2</sub> provides a more comprehensive understanding of vitamin D metabolism. Previous studies have primarily

focused on total 25(OH)D<sub>3</sub> levels, overlooking the potential role of 25(OH)D<sub>2</sub> in maintaining overall vitamin D status (27-29). Given these considerations, this study aims to explore the presence and significance of 25(OH)D<sub>2</sub> in healthy individuals, contributing to a more detailed assessment of vitamin D homeostasis across different populations. One possible reason for the higher production of 25(OH)D<sub>3</sub> over 25(OH)D<sub>2</sub> could be the increased hydroxylation efficiency of vitamin D<sub>3</sub>. In our current study, 25(OH)D<sub>3</sub>, rather than 25(OH) D<sub>2</sub>, seems to be the primary contributor to overall 25(OH)D<sub>3</sub> levels. A possible explanation for the difference between 25(OH)D<sub>2</sub> and 25(OH)D<sub>3</sub> may be the lower affinity of vitamin D<sub>2</sub> metabolites for VDBP, resulting in a shorter half-life and quicker clearance from the bloodstream (30). Additionally, it has been shown that 1,25(OH)<sub>2</sub>D<sub>2</sub> undergoes a more rapid inactivation phase during 24-hydroxylation, whereas 1,25,24(OH)<sub>3</sub>D<sub>3</sub> requires further steps for deactivation. These findings suggest that 25(OH)D<sub>3</sub> remains physiologically active for a longer period, thereby playing a direct role in sustaining vitamin D levels (3). Research by Shieh et al. comparing high doses of vitamin D<sub>2</sub> and D<sub>3</sub> found that vitamin D<sub>3</sub> increased both total and free 25(OH)D levels more effectively than vitamin D<sub>2</sub> (13). Our results, based on 25(OH)D<sub>3</sub> levels measured by LC-MS and free vitamin D levels calculated using the Bikle method, align with the literature and point to vitamin D deficiency, rather than low 25(OH)D<sub>2</sub> levels, as the likely issue. Moreover, 25(OH)D<sub>3</sub> and free vitamin D appear to be better markers of vitamin D bioactivity than 25(OH)D<sub>2</sub>, making them the more reliable indicators of physiological vitamin D sufficiency. In our Turkish research population, we also discovered that females had greater levels of 25(OH)D<sub>3</sub> than males. Similar results have also been noted in Indian (31), and Norwegian (32) sample populations, but not in Saudi (33) populations, despite the anthropometric, ethnic, and geographic disparities in the populations. These findings may reflect physiological differences between males and females, such as variations in PTH levels, or cultural factors, like differences in sun exposure, or possibly a combination of both. Previous studies have indicated that variations in total 25(OH)D levels and VDBP gene polymorphisms may account for the differences in free and bioavailable 25(OH)D levels among healthy Turkish individuals. This points to the significant role of genetic factors in influencing vitamin D metabolite levels (16). 25(OH)D<sub>3</sub>, 25(OH)D<sub>2</sub> and free vitamin D levels were compared between vitamin D deficient and non-deficient groups. It is generally observed that the deficient group exhibited significantly lower 25(OH)D<sub>3</sub> levels and lower free vitamin D levels, possibly in combination with 25(OH)D<sub>2</sub> (Table 2). Conversely, the non-deficient group presents higher levels of

these metabolites, particularly 25(OH)D<sub>3</sub>, reflecting normal vitamin D status. This underscores the role of vitamin D in maintaining overall health and suggests that 25(OH)D<sub>3</sub> is the key form linked to sufficient vitamin D levels.

Our study has some limitations. First, the sample size was relatively small. Second, although 50 participants had total 25(OH)D<sub>3</sub> levels below 20 ng/mL, indicating a considerable proportion of subjects with lower total 25D levels, the sample may not fully represent broader trends. Third, this study did not include a follow-up after vitamin D supplementation, which could have provided additional insights into distinguishing vitamin D deficiency. Additionally, the healthy participants were not severely deficient in vitamin D.

#### CONCLUSION

Despite these limitations, the study provides valuable insights into comparing free vitamin D and 25(OH)D<sub>2</sub> levels with 25(OH)D<sub>3</sub> levels in healthy Turkish individuals. Our findings indicate that 25(OH)D<sub>3</sub> and free vitamin D play a more

significant role in determining vitamin D metabolite levels than 25(OH)D<sub>2</sub>. Further research is necessary to explore whether variations in vitamin D metabolite levels are linked to specific vitamin D dosages and supplements, and to better understand the influence of dietary, sex, ethnic, and endocrine factors—such as PTH—on these physiological interactions.

**Statement of Ethics:** The study was approved by Biruni University Non-Interventional Research Ethics Committee (Approval No: 2020/43-20). Written informed consent was obtained from all participants.

**Conflict of Interest Statement:** The authors declare that there was no conflict of interest.

**Funding Sources:** This research received no external funding.

**Data Availability Statement:** The data of serum 25(OH)D<sub>3</sub>, albumin and VDBP concentrations of 51 individuals were used for a previously published study of the authors in which VDBP gene polymorphisms were investigated [19].

#### REFERENCES

1. Wang S. Epidemiology of vitamin D in health and disease. *Nutr Res Rev.* 2009;2(22):188-203
2. Zelzer S, Prüller F, Curcic P, Sloup Z, Holter M, Herrmann M, et al. Vitamin D Metabolites and Clinical Outcome in Hospitalized COVID-19 Patients. *Nutrients.* 2021;7(13):
3. Ramasamy I. Vitamin D Metabolism and Guidelines for Vitamin D Supplementation. *Clin Biochem Rev.* 2020;3(41):103-26
4. Nikolac Gabaj N, Unic A, Miler M, Pavicic T, Culej J, Bolanca I, et al. In sickness and in health: pivotal role of vitamin D. *Biochem Med (Zagreb).* 2020;2(30):020501
5. Al-Thagfan, S S, Alolayan SO, Ahmed S, Emar M M, Awadallah MF, et al. Impacts of deficiency in vitamin D derivatives on disease severity in adult bronchial asthma patients. *Pulm Pharmacol Ther.* 2021;70):102073
6. Jenkinson C. The vitamin D metabolome: An update on analysis and function. *Cell Biochem Funct.* 2019;6(37):408-23
7. Bikle D. Vitamin D: production, metabolism and mechanisms of action. Europe PMC; 2015.
8. Haussler MR., Whitfield GK, Kaneko I, Haussle CA, Hsieh D, Hsieh JC, et al. Molecular mechanisms of vitamin D action. *Calcif Tissue Int.* 2013;2(92):77-98
9. Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Köstenberger M, Tmava Berisha A, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. *Eur J Clin Nutr.* 2020;11(74):1498-513
10. Glendenning P, Chew GT, Inderjeeth CA, Taranto M, Fraser WD, et al. Calculated free and bioavailable vitamin D metabolite concentrations in vitamin D-deficient hip fracture patients after supplementation with cholecalciferol and ergocalciferol. *Bone.* 2013;2(56):271-5
11. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney, R. P., ... & Weaver, C. M. ( et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;7(96):1911-30
12. Holick MF, Biancuzzo RM, Chen TC, Klein EK., Young A, Bibuld D, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. *J Clin Endocrinol Metab.* 2008;3(93):677-81
13. Shieh A, Chun RF, Ma C, Witzel S, Meyer B, Rafison B, et al. Effects of High-Dose Vitamin D2 Versus D3 on Total and Free 25-Hydroxyvitamin D and Markers of Calcium Balance. *J Clin Endocrinol Metab.* 2016;8(101):3070-8
14. Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D'Erasmus E., ... et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. *J Clin Endocrinol Metab.* 2008;8(93):3015-20
15. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. *Am J Clin Nutr.* 2001;2(73):288-94
16. Karcioğlu Batur L, Özyayın A, Maviş ME, Gürsu GG, Harbige L, Hekim N.. Vitamin-D Binding Protein Gene Polymorphisms and Serum 25-Hydroxyvitamin-D in a Turkish Population. *Metabolites.* 2021;10(11):

17. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab.* 2011;1(96):53-8
18. A M Mondul, S J Weinstein, J Virtamo & D Albanes . Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. *Br J Cancer.* 2012;9(107):1589-94
19. Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, et al. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. *J Bone Miner Res.* 2011;7(26):1609-16
20. Galior K, Ketha H, Grebe S, Singh RJ, et al. 10 years of 25-hydroxyvitamin-D testing by LC-MS/MS-trends in vitamin-D deficiency and sufficiency. *Bone Rep.* 2018;8):268-73
21. Ferrari D, Lombardi G, Banfi G,. Concerning the vitamin D reference range: pre-analytical and analytical variability of vitamin D measurement. *Biochem Med (Zagreb).* 2017;3(27):030501
22. Stepman HC, Vanderroost A, Van Uytvanghe K, & Thienpont LM, et al. Candidate reference measurement procedures for serum 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 by using isotope-dilution liquid chromatography-tandem mass spectrometry. *Clin Chem.* 2011;3(57):441-8
23. Tripkovic L, Wilson LR, Hart K, Johnsen S, De Lusignan S, Smith CP, et al. Daily supplementation with 15 mug vitamin D(2) compared with vitamin D(3) to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial. *Am J Clin Nutr.* 2017;2(106):481-90
24. Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, . et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. *Am J Clin Nutr.* 2012;6(95):1357-64
25. Heaney RP, Recker RR, Grote J, Horst RL, Armas L, A et al. Vitamin D(3) is more potent than vitamin D(2) in humans. *J Clin Endocrinol Metab.* 2011;3(96):E447-52
26. Horst R, Prapong S, Reinhardt T, Koszewski N, Knutson J, Bishop C. Comparison of the relative effects of 1,24-dihydroxyvitamin D(2) [1, 24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1,24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] on selected vitamin D-regulated events in the rat. *Biochem Pharmacol.* 2000;5(60):701-8
27. Zhu T, Zhao J, Zhuo S, Hu Z, Ouyang S, Wunier Y,. et al. High Fat Diet and High Cholesterol Diet Reduce Hepatic Vitamin D-25-Hydroxylase Expression and Serum 25-Hydroxyvitamin D3 Level through Elevating Circulating Cholesterol, Glucose, and Insulin Levels. *Mol Nutr Food Res.* 2021;65(21):2100220.
28. Hanel A, Veldhuizen C, Carlberg C,. Gene-regulatory potential of 25-hydroxyvitamin D3 and D2. *Front Nutr.* 2022;9:910601.
29. Hasan M, Oster M, Reyer H, Wimmers K, Fischer DC,. Efficacy of dietary vitamin D3 and 25 (OH) D3 on reproductive capacities, growth performance, immunity and bone development in pigs. *Br J Nutr.* 2023;130(8):1298-1307.
30. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. *Am J Clin Nutr.* 2006;4(84):694-7
31. Sanghera DK, Sapkota BR, Aston CE, Blackett PR. Vitamin D Status, Gender Differences, and Cardiometabolic Health Disparities. *Ann Nutr Metab.* 2017;2(70):79-87
32. Johnson LK, Hofsø D, Aasheim ET, Tanbo T, Holven KB, Andersen LF, et al. Impact of gender on vitamin D deficiency in morbidly obese patients: a cross-sectional study. *Eur J Clin Nutr.* 2012;1(66):83-90
33. Abudawood M, Tabassum H, Ansar S, Almosa K, Sobki S, Ali MN, et al. Assessment of gender-related differences in vitamin D levels and cardiovascular risk factors in Saudi patients with type 2 diabetes mellitus. *Saudi J Biol Sci.* 2018;1(25):31-36.